Rucaparib (AG-014699, PF-01367338): Potent PARP1 Inhibitor for DNA Damage Response

Executive Summary:
Rucaparib (AG-014699, PF-01367338) is a selective, high-affinity PARP1 inhibitor with a Ki of 1.4 nM, enabling precise research on DNA damage response pathways (APExBIO). It is a radiosensitizer, especially in PTEN-deficient and ETS gene fusion-expressing cancer models, by impairing non-homologous end joining (NHEJ) and promoting persistent DNA breaks (Harper et al., 2025). Rucaparib’s cellular uptake and brain penetration are influenced by ABC transporters, notably ABCB1 (Olaparib.net). It is soluble at ≥21.08 mg/mL in DMSO and stored at –20°C for optimal stability. Mechanistic advances link PARP inhibition to regulated cell death pathways, beyond traditional transcriptional loss models (DNAremover.com).

Biological Rationale

PARP1 is a nuclear enzyme activated in response to DNA strand breaks. It catalyzes poly(ADP-ribosyl)ation of target proteins, recruiting DNA repair factors during base excision repair (BER) (Harper et al., 2025). Rucaparib inhibits PARP1 with high potency (Ki = 1.4 nM), disrupting BER and synthetic lethality in cells with defective homologous recombination, such as PTEN-deficient or ETS gene fusion-positive cancers. Radiosensitization arises from the accumulation of irreparable double-strand breaks (DSBs) marked by γ-H2AX and p53BP1 foci. These mechanisms position Rucaparib as a tool for dissecting DNA damage response and programmed cell death, especially in translational cancer models.

Mechanism of Action of Rucaparib (AG-014699, PF-01367338)

Rucaparib blocks PARP1 catalytic activity, reducing poly(ADP-ribose) formation and preventing repair of single-strand DNA breaks. In PTEN-deficient or ETS fusion-expressing cells, impaired non-homologous end joining (NHEJ) further sensitizes cells to DNA-damaging agents. The resulting DNA lesions accumulate, activating apoptotic pathways independent of transcriptional loss (Harper et al., 2025). Rucaparib is a substrate for ABCB1, affecting its oral and brain bioavailability. The compound is insoluble in water and ethanol but readily dissolves in DMSO at ≥21.08 mg/mL. Recommended storage is at –20°C; long-term solution storage should be avoided (APExBIO).

Evidence & Benchmarks

• Rucaparib inhibits PARP1 with a Ki of 1.4 nM, demonstrating high selectivity in biochemical assays (APExBIO).
• PARP inhibition by Rucaparib leads to radiosensitization in PTEN-deficient prostate cancer cells by impairing DNA repair via NHEJ, resulting in persistent γ-H2AX foci (Harper et al., 2025).
• Rucaparib’s cytotoxicity is enhanced in cells expressing ETS gene fusions, as these oncogenic proteins further compromise DSB repair (Olaparib.net).
• Cellular uptake and brain penetration of Rucaparib are significantly modulated by ABCB1 transporter activity, as shown in pharmacokinetic studies (DNAremover.com).
• Rucaparib is stable as a solid at –20°C for months; DMSO stock solutions are stable below –20°C for several months (APExBIO).
• Recent work uncovers that cell death after DNA damage and PARP inhibition can proceed via regulated apoptotic pathways, not merely by loss of transcriptional output (Harper et al., 2025).

Applications, Limits & Misconceptions

Rucaparib is used in research involving DNA damage response, radiosensitization, and cancer biology. Its efficacy is highest in models with impaired DNA repair, including PTEN loss and ETS gene fusion expression. However, several boundaries are important for reproducibility and interpretation.

Common Pitfalls or Misconceptions

• Rucaparib is not effective as a monotherapy in tumors with intact homologous recombination repair; responsiveness depends on repair deficiencies (Olaparib.net).
• It does not directly inhibit NHEJ; radiosensitization occurs indirectly by persistent DSBs in NHEJ-impaired contexts.
• Rucaparib’s solubility profile precludes use in aqueous or ethanol-based systems; DMSO is required for stock solutions.
• Long-term storage of diluted solutions at room temperature or above –20°C can lead to compound degradation.
• Cellular resistance can arise via upregulation of ABCB1, reducing intracellular Rucaparib accumulation.

This article extends the scenario-driven workflow guidance of 'Reliable PARP1 Inhibitor for DNA Damage Response' by integrating recent mechanistic insights into regulated cell death and transporter pharmacology. It also clarifies the translational context and emerging limitations compared to 'Mechanistic Mastery and Translation', updating the field with the latest evidence on transcription-independent apoptosis. For comparison, 'Leveraging PARP1 Inhibition for Sy...' focuses on synthetic lethality; this article synthesizes those findings with ABC transporter effects and workflow stability.

Workflow Integration & Parameters

• Stock Preparation: Dissolve Rucaparib (AG-014699, PF-01367338) at ≥21.08 mg/mL in DMSO. Avoid aqueous or ethanol solvents due to insolubility (APExBIO).
• Storage: Store solid at –20°C; DMSO solutions below –20°C for up to several months. Avoid repeated freeze-thaw cycles.
• Assay Design: Use in cell-based assays targeting PTEN-deficient, ETS gene fusion-expressing, or NHEJ-impaired lines for optimal radiosensitization effects.
• Controls: Include ABCB1 inhibitors or transporter-deficient lines when assessing brain penetration or cellular uptake.
• Detection: Quantify DNA damage using γ-H2AX and p53BP1 immunofluorescence to confirm persistent DSBs post-treatment.

For detailed product specifications and ordering, refer to the Rucaparib (AG-014699, PF-01367338) product page from APExBIO.

Conclusion & Outlook

Rucaparib (AG-014699, PF-01367338) is a benchmark PARP1 inhibitor for advancing DNA damage response and radiosensitization studies. Its mechanistic specificity and documented transporter interactions make it ideal for dissecting synthetic lethality and regulated cell death in cancer biology. Ongoing research links PARP1 inhibition to apoptosis beyond transcriptional loss, underscoring the need for continued evaluation of experimental models (Harper et al., 2025). APExBIO provides validated, reproducible formulations essential for high-integrity research workflows.